The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Immunotherapy MORE >>

To date, there is no national Medicare policy in place to provide coverage for CAR T-cell therapies, which have been proven to be a successful treatment for certain patients with relapsed/refractory cancers. Now, the Centers for Medicare & Medicaid Services has proposed to cover CAR T-cell therapies approved by the FDA under “Coverage with Evidence Development."

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.